1 Min Read
March 8 (Reuters) - Celyad SA:
* Celyad obtains FDA approval to initiate the NKR-2 CAR T cells THINK trial in the USA Source text for Eikon: Further company coverage: (Gdynia Newsroom)
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.